The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher ...
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
Philadelphia City Council members on Thursday criticized President Donald Trump following a week of chaos for state and local ...
Hosted on MSN22h
HeartBeam submits 510(k) application to FDA for ECG softwareHeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...
In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback